Skip to main content

Table 3 Adverse events ≥grade 3 in the SOX arm (n=53)

From: Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)

 

All grades

Grade 3–4

n (%)

n (%)

Laboratory findings

 Thrombocytopenia

49 (92.5)

10 (18.9)

 Neutropenia

42 (79.2)

7 (13.2)

 Anemia

47 (88.7)

1 (1.9)

 Hypoalbuminemia

46 (86.8)

1 (1.9)

 Increased AST

42 (79.2)

1 (1.9)

 Hyponatremia

23 (43.4)

1 (1.9)

Clinical findings

 Anorexia

25 (47.2)

2 (3.8)

 Paresthesia

36 (67.9)

1 (1.9)

 Fatigue/malaise

21 (39.6)

1 (1.9)

  1. AST: aspartate aminotransferase, SOX: S-1 and oxaliplatin